Development and Evaluation of a Pilot Nurse Case Management Model to Address Multidrug-Resistant Tuberculosis (MDR-TB) and HIV in South Africa

被引:19
|
作者
Farley, Jason E. [1 ]
Kelly, Ana M. [2 ]
Reiser, Katrina [1 ]
Brown, Maria [1 ]
Kub, Joan [1 ,3 ]
Davis, Jeane G. [1 ]
Walshe, Louise [3 ]
Van der Walt, Martie [4 ]
机构
[1] Johns Hopkins Univ, Sch Nursing, Baltimore, MD 21205 USA
[2] Michigan State Univ, Coll Nursing, E Lansing, MI 48824 USA
[3] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA
[4] MRC, TB Epidemiol & Intervent Res Unit, Pretoria, South Africa
来源
PLOS ONE | 2014年 / 9卷 / 11期
基金
美国国家卫生研究院;
关键词
XDR-TB; GUIDELINES; INFECTION; EPIDEMIC; CARE;
D O I
10.1371/journal.pone.0111702
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Setting: Multidrug-resistant tuberculosis (MDR-TB) unit in KwaZulu-Natal, South Africa. Objective: To develop and evaluate a nurse case management model and intervention using the tenets of the Chronic Care Model to manage treatment for MDR-TB patients with a high prevalence of human immunodeficiency virus (HIV) co-infection. Design: A quasi-experimental pilot programme utilizing a nurse case manager to manage care for 40 hospitalized MDR-TB patients, 70% HIV co-infected, during the intensive phase of MDR-TB treatment. Patients were followed for six months to compare proximal outcomes identified in the model between the pre- and post-intervention period. Results: The greatest percent differences between baseline and six-month MDR-TB proximal outcomes were seen in the following three areas: baseline symptom evaluation on treatment initiation (95% improvement), baseline and monthly laboratory evaluations completed per guidelines (75% improvement), and adverse drug reactions acted upon by medical and/or nursing intervention (75% improvement). Conclusion: Improvements were identified in guideline-based treatment and monitoring of adverse drug reactions following implementation of the nurse case management intervention. Further study is required to determine if the intervention introduced in this model will ultimately result in improvements in final MDR-TB treatment outcomes.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] Progress in the roll-out of multidrug-resistant tuberculosis (MDR-TB) treatments
    Heng, M.
    Allmendinger, S.
    Chiang, C-Y.
    Trebucq, A.
    Horsburgh, C. R., Jr.
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2020, 24 (05) : 535 - 536
  • [22] Low-dose amikacin in the treatment of Multidrug-resistant Tuberculosis (MDR-TB)
    Sabur, Natasha F.
    Brar, Mantaj S.
    Wu, Lisa
    Brode, Sarah K.
    BMC INFECTIOUS DISEASES, 2021, 21 (01)
  • [23] Clinical risk factors associated with multidrug-resistant tuberculosis (MDR-TB) in Mali
    Baya, Bocar
    Achenbach, Chad J.
    Kone, Bourahima
    Toloba, Yacouba
    Dabitao, Djeneba K.
    Diarra, Bassirou
    Goita, Drissa
    Diabate, Seydou
    Maiga, Mamoudou
    Soumare, Dianguina
    Ouattara, Khadidia
    Kanoute, Tenin
    Berthe, Gaoussou
    Kamia, Youssouf M.
    Sarro, Yeya Dit Sadio
    Sanogo, Moumine
    Togo, Antieme C. G.
    Dembele, Bindongo P. P.
    Coulibaly, Nadie
    Kone, Amadou
    Akanbi, Maxwell
    Belson, Michael
    Dao, Sounkalo
    Orsega, Susan
    Siddiqui, Sophia
    Doumbia, Seydou
    Murphy, Robert L.
    Diallo, Souleymane
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2019, 81 : 149 - 155
  • [24] Classification of drugs to treat multidrug-resistant tuberculosis (MDR-TB): evidence and perspectives
    Rendon, Adrian
    Tiberi, Simon
    Scardigli, Anna
    D'Ambrosio, Lia
    Centis, Rosella
    Caminero, Jose A.
    Migliori, Giovanni Battista
    JOURNAL OF THORACIC DISEASE, 2016, 8 (10) : 2666 - 2671
  • [25] Low-dose amikacin in the treatment of Multidrug-resistant Tuberculosis (MDR-TB)
    Natasha F. Sabur
    Mantaj S. Brar
    Lisa Wu
    Sarah K. Brode
    BMC Infectious Diseases, 21
  • [26] Multidrug-Resistant Tuberculosis (MDR-TB) in India: An Attempt to Link Biosocial Determinants
    Sachin R Atre
    Nerges F Mistry
    Journal of Public Health Policy, 2005, 26 : 96 - 114
  • [27] Multidrug-resistant tuberculosis (MDR-TB) in India: An attempt to link biosocial determinants
    Atre, SR
    Mistry, NF
    JOURNAL OF PUBLIC HEALTH POLICY, 2005, 26 (01) : 96 - 114
  • [28] Carpe diem ('Seize the day'): Building on the findings of the 2015 World Health Organization evaluation of the multidrug-resistant tuberculosis (MDR-TB) programme to make the most of shortened MDR-TB treatment in South Africa
    Loveday, Marian
    Cox, Helen
    SAMJ SOUTH AFRICAN MEDICAL JOURNAL, 2017, 107 (03): : 176 - 177
  • [29] GeneXpert MTB/RIF Is Superior to BBD Max MDR-TB for Diagnosis of Tuberculosis (TB) in a Country with Low Incidence of Multidrug-Resistant TB (MDR-TB)
    Mokaddas, E. M.
    Ahmad, S.
    Eldeen, H. S.
    JOURNAL OF CLINICAL MICROBIOLOGY, 2019, 57 (06)
  • [30] Factors associated with multidrug-resistant tuberculosis (MDR-TB) in Bhutan: A nationwide case-control study
    Tenzin, Chador
    Chansatitporn, Natkamol
    Dendup, Tashi
    Dorji, Tandin
    Lhazeen, Karma
    Tshering, Dorji
    Pelzang, Thinley
    PLOS ONE, 2020, 15 (07):